All In Biotech

Drug Trial Radar · NCT06211764

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 272 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

272

Actual

Start

Apr 9, 2024

Primary completion

Nov 27, 2030

Study completion Apr 14, 2031

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.

Conditions

  • Non-Muscle Invasive Bladder Neoplasms

Interventions

  • TAR-200Drug

    Participants will receive TAR-200 intravesically.

  • Mitomycin CDrug

    Participants will receive MMC intravesically.

  • GemcitabineDrug

    Participants will receive gemcitabine intravesically.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free Survival (DFS)Time frame: Up to 6 years 7 months

Locations

123 sites in 14 countries. Site status is shown where the registry gives one.

  • Arkansas Urology

    Little Rock, Arkansas

  • Genesis Research LLC 1

    Los Alamitos, California

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • University of California Irvine Medical Center

    Orange, California

  • University of California San Francisco

    San Francisco, California

  • Genesis Research LLC

    Torrance, California

  • Colorado Clinical Research

    Lakewood, Colorado

  • Florida Urology Partners

    Riverview, Florida

  • Northwestern University

    Chicago, Illinois

  • UroPartners

    Chicago Ridge, Illinois

  • Urology of Indiana

    Carmel, Indiana

  • First Urology, PSC

    Jeffersonville, Indiana

  • Wichita Urology Group

    Wichita, Kansas

  • Comprehensive Urology

    Royal Oak, Michigan

  • Specialty Clinical Research of St Louis

    St Louis, Missouri

  • Associated Medical Professionals

    Syracuse, New York

  • The Urology Group

    Cincinnati, Ohio

  • Central Ohio Urology Group

    Gahanna, Ohio

  • Centers for Advanced Urology LLC d b a MidLantic Urology

    Bala-Cynwyd, Pennsylvania

  • Ralph H. Johnson Veterans Affairs Medical Center

    Charleston, South Carolina

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • Low Country Urology Clinics

    North Charleston, South Carolina

  • Urology Associates

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Urology Austin

    Austin, Texas

  • Urology Clinics of North Texas

    Dallas, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Houston Metro Urology

    Houston, Texas

  • Spokane Urology

    Spokane, Washington

  • Clinica Santa Isabel

    Buenos Aires, Argentina

  • Investigaciones Clinico Moleculares (ICM)

    CABA, Argentina

  • Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica

    Córdoba, Argentina

  • Centro Urologico Profesor Bengio

    Córdoba, Argentina

  • Hospital Privado de la Comunidad

    Mar del Plata, Argentina

  • AZ Sint-Jan

    Bruges, Belgium

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Ziekenhuis Oost-Limburg

    Genk, Belgium

  • Algemeen ziekenhuis Maria Middelares

    Ghent, Belgium

  • Algemeen Ziekenhuis Delta

    Roeselare, Belgium

  • Fundacao Pio XII

    Barretos, Brazil

Showing 40 of 123 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.